Edward Woo

Destiny Buch

- NovaBay Pharmaceuticals, Inc. (NBY) **regained compliance** with the NYSE American’s continued listing standards, as formally confirmed by the NYSE American in a letter dated **October 20, 2025**.  **[1389545_1fe009103f964e15bfdc8b1ca7a26a1b_0]** 
- The company had previously been notified on April 18, 2024, and May 28, 2024, of non-compliance with Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide, which require a minimum of **$6 million** in stockholders' equity.  **[1389545_1fe009103f964e15bfdc8b1ca7a26a1b_0]** 
- To address these deficiencies, NovaBay issued and sold pre-funded warrants, generating **approximately $6.0 million** in net proceeds, and issued and sold Series E non-voting convertible preferred stock, generating **approximately $2.15 million** in net proceeds.  **[1389545_1fe009103f964e15bfdc8b1ca7a26a1b_0]** 
- Following these transactions, the company believes its stockholders’ equity now **exceeds the $6 million** minimum requirement.  **[1389545_1fe009103f964e15bfdc8b1ca7a26a1b_0]**

NovaBay Pharmaceuticals (NBY)